Evaluating the Economic Impact of a Targeted Medication Intervention Program

Abstract

Objective: To calculate the return on investment (ROI) for a targeted medication intervention program developed by corporate management of a community pharmacy. Design: Retrospective analysis and cross-sectional survey. Setting: Regional community pharmacy chain in North Carolina. Participants: Targeted medication interventions completed from February 1, 2010, to July 31, 2010, were included in the retrospective analysis. Community pharmacists employed by the pharmacy chain that completed the questionnaire were included in the cross-sectional analysis. Intervention: Targeted medication intervention services were provided to the patient and documented by the pharmacist. Main Outcome Measure: The ROI for a community pharmacist-provided targeted medication intervention program. Results: Of the 180 pharmacists, 69 completed the questionnaire (38% response rate). The average time to complete one targeted medication intervention was calculated to be 22.63 minutes. The total cost for providing a targeted medication intervention program during the study time frame was $15 760.86. Total revenue was $15 216.00; therefore, the program resulted in an ROI to the pharmacy chain of negative 3%. Conclusion: This 6-month study resulted in an ROI to the pharmacy chain of negative 3%. Under the current reimbursement model, for this program to break even, the average time to complete one targeted medication intervention must equal 21.85 minutes or less.

Keywords

medication therapy management pharmacists community pharmacy return on investment targeted medication intervention

Get full access to this article

View all access options for this article.

References

Academy of Managed Care Pharmacy. Sound medication therapy management programs. 2006 consensus document. J Man Care Pharm. 2006;12(3):S1–S15.

Ernst

Grizzle

. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192–199.

Institute of Medicine. Report brief: preventing medication errors. http://www.iom.edu/∼/media/Files/Report%20Files/2006/Preventing-Medication-Errors-Quality-Chasm-Series/medicationerrorsnew.pdf. Accessed October 22, 2012.

American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48(3):341–353.

Schumock

Butler

Meek

Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23(1):113–132.

Perez

Doloresco

Hoffman

Economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 2009;29(1):128.

McMullin

Hennenfent

Ritchie

A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Int Med. 1999;159(19):2306–2309.

Stebbins

Kaufman

Lipton

. The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services. J Manag Care Pharm. 2005;11(4):333–341.

Schommer

Planas

Johnson

Pharmacist-provided medication therapy management (part 1): provider perspectives in 2007. J Am Pharm Assoc. 2008;48(3):354–363.

10.

Schommer

Planas

Johnson

Pharmacist-provided medication therapy management (part 2): payer perspectives in 2007. J Am Pharm Assoc. 2008;48(4):478–486.

11.

Look

Mott

Kreling

Economic impact of pharmacist-reimbursed drug therapy modification. J Am Pharm Assoc. 2011;51(1):58–64.

12.

Carroll

. Estimating the impact of Medicare Part D on the profitability of independent community pharmacies. J Manag Care Pharm. 2008;14(8):768–779.

13.

McDonough

Harthan

McLeese

Retrospective financial analysis of medication therapy management services from the pharmacy’s perspective. J Am Pharm Assoc. 2010;50(1):62–66.

14.

OutcomesMTM™ (formerly, Outcomes Pharmaceutical Health Care^®). http://www.outcomesmtm.com, Accessed October 22, 2012.

15.

Schommer

Doucette

Johnson

Positioning and integrating medication therapy management. J Am Pharm Assoc. 2012;52(1):e1–e13.